Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anne Lesage sold 30,000 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $38.30, for a total transaction of $1,149,000.00. Following the completion of the transaction, the insider owned 56,450 shares of the company’s stock, valued at approximately $2,162,035. The trade was a 34.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Anne Lesage also recently made the following trade(s):

• On Tuesday, June 30th, Anne Lesage sold 30,703 shares of Pharvaris stock. The stock was sold at an average price of $35.49, for a total value of $1,089,649.47.
• On Tuesday, June 30th, Anne Lesage sold 27,872 shares of Pharvaris stock. The stock was sold at an average price of $35.48, for a total value of $988,898.56.
• On Monday, June 29th, Anne Lesage sold 6,997 shares of Pharvaris stock. The stock was sold at an average price of $35.05, for a total value of $245,244.85.
• On Monday, June 29th, Anne Lesage sold 10,600 shares of Pharvaris stock. The shares were sold at an average price of $35.07, for a total transaction of $371,742.00.

Pharvaris Price Performance

PHVS stock traded up $1.42 during trading on Monday, hitting $39.44. 472,347 shares of the stock traded hands, compared to its average volume of 392,807. The stock has a market cap of $2.58 billion, a price-to-earnings ratio of -12.98 and a beta of -2.33. Pharvaris N.V. has a 1 year low of $20.65 and a 1 year high of $43.25. The firm’s 50 day moving average is $35.09 and its two-hundred day moving average is $31.41.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, analysts anticipate that Pharvaris N.V. will post -3.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on PHVS. Guggenheim increased their target price on Pharvaris from $40.00 to $44.00 and gave the company a “buy” rating in a research note on Thursday. Wells Fargo & Company upped their price target on Pharvaris from $55.00 to $65.00 and gave the company an “overweight” rating in a report on Wednesday, September 9th. Leerink Partners lifted their price objective on Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday. Morgan Stanley upped their target price on shares of Pharvaris from $46.00 to $62.00 and gave the company an “overweight” rating in a research note on Wednesday, September 9th. Finally, Royal Bank Of Canada raised their price target on shares of Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a report on Wednesday, September 9th. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $59.50.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. venBio Partners LLC purchased a new position in shares of Pharvaris during the 2nd quarter worth $160,569,809. Deerfield Management Company L.P. increased its stake in shares of Pharvaris by 21.1% in the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock worth $60,939,000 after purchasing an additional 425,000 shares in the last quarter. Wellington Management Group LLP raised its holdings in Pharvaris by 12.9% in the 2nd quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company’s stock worth $82,748,000 after purchasing an additional 274,034 shares during the period. Commodore Capital LP raised its holdings in Pharvaris by 1.6% in the 1st quarter. Commodore Capital LP now owns 1,918,970 shares of the company’s stock worth $54,211,000 after purchasing an additional 29,525 shares during the period. Finally, Paradigm Biocapital Advisors LP lifted its position in Pharvaris by 72.7% during the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock valued at $45,796,000 after purchasing an additional 772,583 shares in the last quarter.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.